Background {#Sec1}
==========

The *NUS1* (nuclear undecaprenyl pyrophosphate synthase 1) gene encodes the Nogo-B receptor (NgBR) \[[@CR1], [@CR2]\], which interacts with dehydrodolichyl diphosphate synthase complex subunit (DHDDS) and promotes *cis*-prenyltransferase (*cis*-PTase) activity. NgBR is an essential catalyst of the dolichol monophosphate (Dol-P) biosynthetic machinery in eukaryotic cells \[[@CR3], [@CR4]\]. The well-conserved C-terminus domain of *cis*-PTase in NgBR has intrinsic effects for protein structure stabilization, in association with N-glycans. To date, four de novo *NUS1* variants have been reported in association with developmental and epileptic encephalopathy (DEE) and early-onset Parkinson's disease, and one homozygous *NUS1* variant has been associated with a congenital disorder of glycosylation. Interestingly, two de novo variants \[[@CR5]\] and a pair of compound heterozygous variants \[[@CR6]\] in *DHDDS* have been reported in five patients with DEE seizures or congenital glycosylation defects, suggesting that pathogenic variants in the NgBR--DHDDS pathway may cause neurological disorders. Here, we report two unrelated Japanese patients with a novel, recurrent, de novo *NUS1* variant, who presented with epileptic seizures with involuntary movement, ataxia, intellectual disability and scoliosis.

Case presentation {#Sec2}
=================

The patient 1 was the second child born to non-consanguineous, healthy parents. Her elder brother had febrile seizures during childhood. She was born spontaneously, at full term, with no asphyxia. Her birth weight was 2826 g (− 0.44 SD). She gained head control at 4 months of age and sat without support at 7 months of age. She experienced febrile seizures at 9 months of age and generalized tonic-clonic convulsions without fever at 14 months of age, at which time valproic acid (VPA) was administered. Tremulous myoclonus of the extremities was also observed. She walked without support at 20 months of age, spoke a meaningful word at 10 months of age and two-word phrases at 24 months of age. Her developmental quotient was 77 at 2 years of age. Her seizures occurred once per year until the age of 6 years and 5 months; however, an increase in the VPA dosage lessened an episode of convulsive attack, after which her seizures disappeared. Her electroencephalograms (EEG) showed 3-Hz, diffuse, spike-and-slow-wave complexes with a 7-Hz slow wave background at 8 years of age (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A), which became worsened at 15 years of age. However, the treatment with VPA and LEV significantly lessened 3-Hz diffuse spike-and-wave complexes and only 3-Hz high-amplitude slow wave bursts were infrequently recorded during sleep at 17 years of age (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B). Her brain magnetic resonance imaging (MRI) results were normal at 6 years of age (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C, S1D) and at 15 years of age (Additional file [1](#MOESM1){ref-type="media"}: Figure S1E, S1F). At the age of 17 years, her height was 157.4 cm (− 0.12 SD) and her weight was 41.9 kg (− 1.42 SD). She had no dysmorphic features except for scoliosis which needed a surgical correction at 15 years of age. She showed dysgraphia, due to tremulous myoclonus of the bilateral extremities (Additional file 4: Movie S1). She showed no behavioral disorders, such as autistic spectrum disorders or attention deficit/hyperkinetic disorder.

**Additional file 4: Movie S1.** Involuntary movements of Patient 1 at 17 years of age. Patient 1 shows frequent eye blinking, multifocal facial twitching, tremulous myoclonus of the upper extremities, mild dysmetria, and clumsiness of diadochokinesis.

In patient 1, trio (sequencing with parents) WES was performed, and 5 de novo variants were detected (Additional file [5](#MOESM5){ref-type="media"}: Table S1 and Additional file [6](#MOESM6){ref-type="media"}: Table S2 and Additional file [7](#MOESM7){ref-type="media"}: Supplemental method). Patient 1 had a splice site variant in *NUS1* \[NM_138459.4:c.691 + 1C \> A\] on chromosome 6q22.1 (chr6: 118,015,344). This variant was absent from public databases (allele frequency was 0 in ExAC, gnomAD, ESP6500, HGVD, ToMMo and in-house 575 Japanese exome controls). Multiple *in-silico* evaluation scores for predicting the pathogenicity of DNA sequence alternations suggest that this variant is deleterious: Mutation Taster (<http://www.mutationtaster.org/>) returned a value of disease causing; CADD (<https://cadd.gs.washington.edu/>) returned a value of 25.9; and Fathmm (<http://fathmm.biocompute.org.uk/>) returned a value of deleterious. This splice variant is predicted \[[@CR7]\] to create a new splice donor site, which could change the reading frame and introduce a premature termination codon (PTC).

The patient 2 was born normally to non-consanguineous, healthy parents. His birth weight was 3550 g. At the age of 6, it was noticed he had speech delay, clumsiness of the hands, and involuntary movements of the hands when he used chopsticks. At the age of 8 years, he was suspected to have a cerebellar atrophy, with seizures. Occasionally, jerky movements of the limbs also appeared. From 14 years of age, he gradually developed a gait abnormality. At the age of 37 years, he was admitted to hospital. On physical examination, he showed flat foot and limb ataxia. Clonazepam was remarkably effective for treating his gait disturbance. Laboratory examinations were all normal, including lactic acid, pyruvic acid, vitamins, the thyroid gland, ceruloplasmin, copper, lipoproteins, amino acid analysis and leukocyte lysosome enzyme activities (α-galactosidase, β-galactosidase, β-hexosaminidase and arylsulfatase). Genetic testing for dentatorubral-pallidoluysian atrophy was negative. At the age of 40 years, myoclonic jerks of the limbs developed, in addition to ataxia. He was diagnosed as progressive myoclonus epilepsy with an unknown cause. At the age of 42 years, scoliosis became apparent. Starting at the age of 48 years, he began to require assistance with walking. At the latest examination (59 years), he showed intellectual disability (equivalent to that of a 6-year-old), excessive blinking due to tenseness, and profound action myoclonus of the limbs, which could be referred to "hyperkinésie volitionnelle". His eye pursuit was saccadic, and his speech was explosive. Tendon reflexes were slightly increased, and no sensory disturbances were observed. An EEG analyzing jerk-locked back averaging potentials suggested that the myoclonus emerged from the cortex. Examinations of MRI, nerve conduction studies, conventional EEGs, and laboratory examinations of the cerebrospinal fluid and blood were almost within normal ranges (Additional file [2](#MOESM2){ref-type="media"}: Figure S2A, S2B). Increasing the dosage of clonazepam up to 12 mg (0.5 mg × 24 tablets/day) did not alleviate neurological symptoms; however, the oral administration of 50 mg baclofen remarkably lessened myoclonus and slightly improved gait disturbance.

We performed proband-only WES in patient 2 and detected a splicing site alteration variant in *NUS1* \[c.691 + 1C \> A\] and a stop-gain variant in *SPTAN1* \[c.2311G \> T:p.(Glu771\*)\]. These two variants were confirmed by Sanger sequencing using the parents' DNA, and only the *NUS1* variant \[c.691 + 1G \> A\] occurred de novo (Fig. [1](#Fig1){ref-type="fig"}a and Additional file [7](#MOESM7){ref-type="media"}: Supplemental method). *SPTAN1* variant was inherited from healthy mother. Therefore, its pathogenicity should be minimal in the patient. Fig. 1**a** Schematic presentation of the familial pedigrees of patients 1 and 2, with electropherograms of the heterozygous *NUS1* variant occurring de novo. **b** Schematic presentation of the *NUS1* gene structure, with identified variants that result in abnormal cDNA. Based on the cDNA sequencing, the variant \[c.691 + 1G \> A\] creates a new splice donor site in the middle of exon 3 \[c.601_602\], resulting in the loss of a 91-bp section of the *NUS1* exon 3. **c** Comparison of the gene expression levels between a control and a patient. Patient LCLs were cultured either with no treatment (NT) or with cycloheximide (CHX) to test NMD involvement. Gene expression was normalized to that of GAPDH. Error bars represent the 10th to 90th percentiles. The vertical numbers (Y-axis) represent the levels of relative gene expression. **d** Pathogenic *NUS1* variants (including the current variant) mapped to the gene and the protein. A prenyltransferase domain is encoded by the middle of exons 2 to 5. Wild-type protein has 293 amino acids, and the prenyltransferase domain is composed of amino acids 156 to 292. This figure was designed using SMART software (<http://smart.embl-heidelberg.de/>)

To test whether this variant causes aberrant splicing, we examined the cDNA from both individuals' lymphoblastoid cell lines, which revealed that the mutant allele has a 1-base alternation in the splice donor site (chr6:118,015,344) creating a new splice donor site of GT in exon 3 (chr6:118,015,253), resulting in a 91-bp deletion in the *NUS1* exon 3 (Fig. [1](#Fig1){ref-type="fig"}b). Electropherograms of both individuals' cDNA showed that a 91-bp region of exon 3 is missing. TA-cloning of the short RT-PCR product confirmed the same event in the mutant allele (Fig. [1](#Fig1){ref-type="fig"}b, Additional file [3](#MOESM3){ref-type="media"}: Figure S3A and Additional file [7](#MOESM7){ref-type="media"}: Supplemental method). This variant creates a new reading frame \[c.601_691del:p.(Arg202Glnfs\*9)\] and produces a PTC at chr6:118,024,795 (73-bp upstream of the 3′ exon-exon junction) (Fig. [1](#Fig1){ref-type="fig"}b). According to the major rule of nonsense-mediated mRNA decay (NMD) \[[@CR8]\], the mRNA of the mutant allele should be subjected to NMD. However, the results of both individuals' cDNA sequencing chromatograms showed that cycloheximide (an NMD inhibitor) treatment did not recover the peak height of the electropherogram, suggesting that NMD is not involved. Thus, we performed a quantitative analysis using RT-PCR (see Additional file [7](#MOESM7){ref-type="media"}: Supplemental method). RT-PCR showed that the relative gene expression levels of *NUS1* was slightly reduced in the patients' LCLs, with possible minor recovery following cycloheximide treatment (Fig. [1](#Fig1){ref-type="fig"}c). These results support the prediction that the transcribed mRNA of the mutant allele is only partially subjected to NMD.

Discussion and conclusions {#Sec3}
==========================

As the pLI score \[[@CR9]\] of *NUS1* in the ExAC browser is 0.87, suggesting that an intolerance to *NUS1* loss-of-function variants, *NUS1* variants may lead to diseases through haploinsufficiency. Diseases-associated, autosomal-dominant loss-of-function variants in *NUS1* have been identified in patients with the following disorders: developmental delays and epileptic encephalopathy, \[c.743delA:p.(Asp248Alafs\*4)\], \[c.128_141dup:p.(Val48Profs\*7)\] and an approximately 1.3-kb deletion of exon 2 \[[@CR5]\]; and a congenital disorder of glycosylation, \[c.869G \> A:p.(Arg290His)\] \[[@CR10]\]; and early-onset Parkinson's disease, \[c.691 + 3dupA\] \[[@CR11]\]. In addition, microdeletions involving *NUS1* have been linked to pediatric epilepsy \[[@CR12], [@CR13]\]. The four loss-of-function variants identified in *NUS1* occurred de novo (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}d). These variants are located on the C-terminus *cis*-PTase domain, which is well-conserved in mammals. The *cis*-PTase domain interacts with DHDDS, and NgBR influences N-linked protein glycosylation via the regulation of *cis*-PTase activity \[[@CR3]\] (Fig. [1](#Fig1){ref-type="fig"}d). A previous study \[[@CR10]\] reported a homozygous variant, \[c.869G \> A:p.(Arg290His)\] (Fig. [1](#Fig1){ref-type="fig"}d), in siblings with a congenital glycosylation disorder, congenital scoliosis and developmental delay, and refractory epilepsy. This mutation was found to decrease *cis*-PTase activity in the patients' fibroblasts and caused a defect in the dolichol biosynthesis pathway. There are some phenotypic similarities among patients with *NUS1* variants, regardless of inheritance patterns. The two individuals with the de novo \[c.691 + 1C \> A\] variant identified in our study share similar phenotypes: epilepsy, involuntary movement, ataxia, intellectual disability, and scoliosis (Table [1](#Tab1){ref-type="table"}). Table 1Clinical features of individuals with *NUS1* variantsOriginThis studyGuo et al.Hamdan et al.Park et al.IndividualsPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Mutationc.691 + 1C \> Ac.691 + 1C \> Ac.691 + 3dupAc.743delAc.128_141dupexon 2 deletion, 1.3 kbc.869G \> Ac.869G \> AAmino acid changec.601_691del:p.(Arg202Glnfs\*9)c.601_691del:p.(Arg202Glnfs\*9)--(p.Asp248Alafs\*4)(p.Val48Profs\*7)--p.Arg290Hisp.Arg290HisZygosityde novode novode novode novode novode novohomozygoushomozygousAge17 years59 years26 years8 years 9 months15 years29 yearsDeceased at 29 months4 yearsSexFemaleMaleFemaleMaleMaleFemaleMaleMaleConsanguinityNoNo*N/AN/A*NoNo*N/AN/A*EthnicityJapaneseJapaneseChinese Han*N/A*French-CanadianCaucasianCzechsCzechsBirth weight2826 g (−0.44 SD)3500 g*N/AN/A*2489 g*N/AN/AN/A*Birth lengthN/A56 cm*N/AN/AN/AN/AN/AN/A*Age at seizure onset9 months8 years16 years12 months10 months2.5 years11 months7 monthsType of seizuresFebrile seizure at 9 months, generalized tonic-clonic convulsion without fever at 14 months, status epilepticus at 6 years 3 monthsLoss of consciousness without convulsion at 8 years*N/A*Generalzed myoclonic epilepsy, convulsive epilepsy, nocturnal jerksMyoclonic absences with behavioural arrest, facial and palpebral myoclonusMyoclonic absences with behavioural arrest and eyelid flutters, as well as limb myoclonusTonic-clonic seizures, refractory epilepsy and recurrent attacks of "status epilepticus"Refractory epilepsy, severe seizureFrequency of seizuresSeizure-free since 6 years of ageN/A*N/AN/A*5 times a day, lasting 5--10 s1--2 times a weekN/AN/AType of EEG3-Hz, diffuse, spike-and-slow-wave, complexed with 7-Hz, slow wave background8--9 Hz slow α rhythm background with no epileptiform activity*N/A*Bifrontal epileptiform activityDiffuse background slowing, with rhythmic, bifrontal, high-amplitude theta dischargesGeneralized spike-wave and poly-spike wave activityN/AN/AEffective medicines for seizuresValproic acid was effective for seizures, levetiracetam lessened 3-Hz, diffuse, spike-and-slow wave complexesMyoclonus lessened with 50 mg baclofen*N/A*Levetiracetam*N/A*Relatively well-controlled with a combination of valproic acid, lamotrigine and clonazepamN/AN/ABrain MRINormal at 20 months,slight cerebellaratrophy at 14 yearsNormalNormalNormal (2 years 3 months)Normal (8 years)NormalN/ASevere cortical atrophyIntellectual disabilityMild to moderateModerate*N/A*ModerateModerateMildYesN/ALanguage delayMild (speaking two-word sentences at 2 years)YesNoYesMildNoN/AN/ADevelopmental delayMild psychomotor delayNo*N/A*YesYesMild motor delayYesN/AAtaxiaYesYes*N/A*YesNoNoN/AN/AAutsimNoNo*N/AN/A*Yes*N/A*N/AN/AScoliosisYes (operation at 15 years of age)Yes*N/AN/AN/AN/A*Yes, congenitalYes, congenitalHypotoniaNoNo*N/AN/AN/AN/A*SevereSevereDysmorphic featuresNoNo*N/AN/A*No*N/A*MicrocephalyMicrocephalyAdditional featuresDysgraphia due to tremulous myoclonus of bilateral extremitiesEye pursuits were saccadic, hyperkinesie volitionelle-like movement, cortical myoclonusParkinson's disease, asymmetric onset, bradykinesia, resting tremor in limbs, mild gait difficulties----Eye pursuits were saccadic, but saccades were normalHistophathological examination of autopsy tissue revealed non-specific neuronal loss in brain cortex and cerebellum--*N/A* Not available, Not assessed

The newly identified variant in this study created a PTC 73 nucleotides upstream of the last exon-exon junction (Fig. [1](#Fig1){ref-type="fig"}b), which should be subjected to NMD according to the \< 50-bp rule of escaping from NMD \[[@CR8]\]. We speculate that NMD was not fully induced in the studied patients, based on the results of our comparative gene expression analyses (Fig. [1](#Fig1){ref-type="fig"}c). A previous study \[[@CR11]\] of the splice site mutation \[c.691 + 3dupA\] showed a larger decrease in mRNA expression compared with the results in our study. This inconsistency may be due to differences in the variants or to different cells being tested. Although the mutant allele is expressed, our study predicted that the variant results in aberrant splicing, resulting in the expressed NgBR lacking an important functional domain.

In conclusion, we found a recurrent, de novo variant in *NUS1*, \[c.691 + 1C \> A\], in two unrelated individuals. Both individuals had a similar phenotype: epil7epsy, involuntary movement, ataxia, intellectual disability, and scoliosis. This study strongly suggests that loss-of-function variants in *NUS1* that result in the loss of the *cis*-PTase domain in the C-terminus of NgBR may cause neurological disorders with scoliosis.

Supplementary information
=========================

 {#Sec4}

**Additional file 1: Figure S1.** (EEG and MRI of Patient 1). Interictal electroencephalogram (EEG) of Patient 1. A 3-s burst of 3-Hz, frontal-dominant, diffuse, spike-and-slow wave complexes is shown on an EEG at the age of 8 years (A). an EEG at 17 years (B) shows a similar burst of 3-Hz, high-amplitude (\> 300 μV), slow waves, but no noticeable spike discharges. Brain MRIs for Patient 1 at the age of 6 years (C and D) and 15 years (E and F). T2-weighted axial images (C and E) and T1-weighted midsagittal images (D and F) show normal findings. **Additional file 2: Figure S2.** (MRI of Patient 2). Brain MRIs of Patient 2 at the age of 56 years (A and B). T2-weighted axial image (A) and T1- weighted midsagittal image (B) show normal findings. **Additional file 3: Figure S3.** A Agarose gel electrophoresis of cDNA fragments. B Gene expression levels of *NUS1*, normalized to those of actin. RT-PCR primers were same as those reported by Guo et al. \[[@CR11]\]. Gene expression level was normalized to the expression level of actin: 5′-CCGGAAGATGGAAAAGCAGA-3′ (forward), 5′-TCCTTTCCTCCACAAGCCT-3′ (reverse). Gene expression levels were compared to those of control (ctrl) and no cycloheximide treatment (NT) conditions. **Additional file 5: Table S1.** Process of variant filtering for patient 1. **Additional file 6: Table S2.** Detailed information for the five de novo variants found in patient 1, including in silico prediction scores and allele frequencies. **Additional file 7:** Supplemental Method.

*cis*-PTase

:   *cis*-prenyltransferase

DEE

:   Developmental and epileptic encephalopathy

DMSO

:   Dimethyl sulfoxide

EEG

:   Electroencephalogram
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:   Lymphoblastoid cell lines

MRI

:   Magnetic resonance imaging

NgBR

:   Nogo-B receptor

NMD

:   Nonsense mediated mRNA decay

NUS1

:   Nuclear undecaprenyl pyrophosphate synthase 1

PTC

:   Premature termination codon

SNV

:   Single nucleotide variant

VPA

:   Valproic acid

WES

:   Whole-exome sequencing
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